Dr. Reddy's Laboratories received the first US FDA tentative approval for a generic lenacapavir, the twice-yearly injection for HIV pre-exposure prophylaxis (PrEP), announced on 2 November 2026.
Under a September 2025 deal with Unitaid, CHAI and Wits RHI, it will cost about US$40 per person per year in the 120 low- and middle-income countries covered by Gilead's voluntary licence.
First supplies are expected before the end of 2026, with wider availability in 2027; WHO prequalification and national approvals are still needed.
The approval came 16 months after the FDA approved Gilead's originator, Yeztugo, for HIV prevention in June 2025.
HIV's genetic material sits inside a cone-shaped capsid made of p24 protein. Lenacapavir binds between these subunits and disrupts several stages of viral replication. PrEP means taking a drug BEFORE exposure to prevent infection; PEP is taken after exposure.
Simple Analogy: Jamming the lock on the box that carries the virus's instructions.
Indian generic drug maker; founded in 1984 by K. Anji Reddy
Global health financing partnership hosted by WHO; set up in 2006
Partner in the US$40 access agreement
Wits Reproductive Health and HIV Institute, University of the Witwatersrand; partner in the agreement
US drug regulator that grants tentative approvals to generics
FDA approves lenacapavir as Sunlenca to treat multidrug-resistant HIV
Gilead grants royalty-free voluntary licences to six generic makers for 120 countries
FDA approves Yeztugo, the twice-yearly PrEP injection
WHO recommends injectable lenacapavir as an additional HIV prevention option (IAS 2025, Kigali)
Dr. Reddy's, Unitaid, CHAI and Wits RHI agree on the US$40-a-year price
FDA tentative approval for Dr. Reddy's generic
GS Paper III > Science and Technology > Biotechnology and health; GS Paper II > Health
General Awareness > Science and health in news
Pre-exposure prophylaxis: medicine taken before possible exposure to HIV to prevent infection
FDA clearance of a generic that meets standards but cannot be marketed in the US while patents run
Permission a patent holder grants generic makers to produce a drug for specified countries